Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma

NCT02346032 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

4

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Cancer

Interventions

DRUG: refametinib

Sponsor

Samsung Medical Center